Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Scleroderma.

G Asboe-Hansen

    Journal of the American Academy of Dermatology
    |July 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    This study reviews scleroderma pathogenesis and pathology, exploring agents that inhibit connective tissue and collagen formation for therapeutic use. Effective scleroderma treatment requires regular monitoring of disease activity using quantitative techniques to guide therapy adjustments.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Serum and urinary aminoterminal type III procollagen peptide in progressive systemic sclerosis: relationship to sclerodermal involvement, serum hyaluronan and urinary collagen metabolites.

    The Journal of rheumatology·1988
    Same author

    Blister spreading, a diagnostic test in pemphigus. Loss of epidermal and dermoepidermal cohesion.

    Archives of dermatological research·1988
    Same author

    Bioavailability of D-penicillamine in relation to gastrointestinal involvement of generalized scleroderma.

    Scandinavian journal of rheumatology·1987
    Same author

    Bioavailability of D-penicillamine in a patient with gastrointestinal progressive systemic sclerosis.

    Scandinavian journal of rheumatology·1986
    Same author

    Secretion of type IV collagen by keratinocytes of human adult.

    The Journal of investigative dermatology·1985
    Same author

    Development of polyneuropathy during thalidomide therapy.

    The British journal of dermatology·1985
    Same journal

    Localized radiation therapy provides more durable disease control than topical steroids in stage IA mycosis fungoides.

    Journal of the American Academy of Dermatology·2026
    Same journal

    Atypical fibroxanthoma, pleomorphic dermal sarcoma, and undifferentiated sarcoma: Updates on diagnosis, management, and surveillance.

    Journal of the American Academy of Dermatology·2026
    Same journal

    Response to Li et al., "Comment on Nie et al. (2026) 'Suicidality Reports in Acne Patients Treated with Isotretinoin and Concomitant Antidepressants: A Descriptive Analysis of FDA Adverse Event Reporting System Data'".

    Journal of the American Academy of Dermatology·2026
    Same journal

    Treatment Utilization Patterns in Cutaneous Lupus Erythematosus: A Single-Center Retrospective Analysis.

    Journal of the American Academy of Dermatology·2026
    Same journal

    Hypoactive Sexual Desire Disorder in Menopausal Women: Dermatologic Implications of Antiandrogen and Testosterone Therapy.

    Journal of the American Academy of Dermatology·2026
    Same journal

    Incise parallel, section perpendicular to the dermatoglyphs for diagnosis of acral melanocytic lesions-A comment on Thakker et al.

    Journal of the American Academy of Dermatology·2026
    See all related articles

    Area of Science:

    • Rheumatology
    • Dermatology
    • Biochemistry

    Background:

    • Scleroderma is a complex connective tissue disease characterized by excessive fibrosis.
    • Understanding the pathogenesis and pathology of scleroderma is crucial for developing effective treatments.
    • Collagen biosynthesis is a key target for antifibrotic therapies.

    Purpose of the Study:

    • To review the pathogenetic and pathologic aspects of scleroderma.
    • To explore experimental agents that inhibit connective tissue formation, particularly collagen biosynthesis.
    • To discuss the clinical application of these agents in scleroderma therapy.

    Main Methods:

    • Review of existing literature on scleroderma pathogenesis and pathology.
    • Analysis of experimental data on agents inhibiting collagen biosynthesis.
    • Discussion of clinical therapeutic strategies for scleroderma.

    Main Results:

    • Identified agents that effectively inhibit connective tissue and collagen formation.
    • Demonstrated the potential transferability of these agents to clinical scleroderma therapy.
    • Highlighted the importance of quantitative and semiquantitative techniques for monitoring disease activity and guiding treatment.

    Conclusions:

    • Agents inhibiting collagen biosynthesis show promise for scleroderma treatment.
    • Close monitoring of disease activity is essential for successful therapeutic management.
    • Quantitative assessment enables timely detection of treatment failure or disease recurrence.